Trials / Completed
CompletedNCT04730843
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 Administered as a Single Agent in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Elpiscience Biopharma, Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 Agonist) administered as a single agent in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ES102 | ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle. |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2024-03-01
- Completion
- 2024-03-01
- First posted
- 2021-01-29
- Last updated
- 2025-06-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04730843. Inclusion in this directory is not an endorsement.